GreaterSTLInc logo

News & Articles

STL Biotech Sector Continues Growth with Wugen Expansion

Greater St. Louis, Inc. business attraction team helps cancer-fighting startup expand presence, add high tech jobs to the metro
March 22, 2022
Illinois Named Top Ten State for Military Members and Families

Highlighting the continued growth and strength of St. Louis’ biotech scene, cancer-fighting startup Wugen announced its expansion in the Cortex Innovation Community.

“Access to world-class talent, research, education, and facilities in Cortex – as well as the Danforth Center, BioSTL, and other thriving centers — is a critical reason the STL 2030 Jobs Plan identified biotech as a key driver of future economic growth for our metro,” said Greater St. Louis, Inc. CEO Jason Hall. “Biotech companies like Wugen successfully scaling in St. Louis metro is a reminder of why we are leaning into our industry strengths and the unique value proposition our community provides to cutting-edge biotech firms.”

Founded in 2018 and created via technology licensed from Washington University, Wugen recently announced a $200 million capital raise and the launch of clinical trials for its second cancer-fighting drug. The company, which develops off-the-shelf cell therapies for cancer, is currently based at BioGenerator Labs inside the BioSTL Building in the Cortex district. The expansion, which GSL’s business attraction team helped bring to fruition, will allow Wugen to double its workforce to 100 employees and will see the company occupy the entire first floor of 4260 Forest Park Avenue.

“We are proud to be part of St. Louis’ vibrant biotech community and are pleased to continue to grow locally,” said Dan Kemp, Wugen’s CEO and president.